NYSE:NTB
NYSE:NTBBanks

Is Bank of N.T. Butterfield & Son (NTB) Pricing Reflect Its Strong Recent Share Performance?

If you are wondering whether Bank of N.T. Butterfield & Son at around US$50.36 is priced attractively or not, the key question is how that share price stacks up against its underlying value. The stock has returned 1.3% over the last 7 days, 0.0% over the past 30 days and 1.3% year to date, while the 1 year and 3 year returns sit at 49.8% and 87.7% respectively. This makes the current level especially interesting for anyone thinking about risk and reward. Recent trading interest has been...
NasdaqGS:TWST
NasdaqGS:TWSTBiotechs

What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?

In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments in institutional holdings. At the same time, multiple brokerage firms reiterated positive views on Twist Bioscience’s semiconductor-based DNA synthesis platform, collectively maintaining an “Outperform” stance backed by confidence in its synthetic biology technology. Building on this renewed...
NasdaqCM:CAPR
NasdaqCM:CAPRBiotechs

Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal

Capricor Therapeutics recently reported that its Phase 3 trial of deramiocel met both primary and secondary endpoints and entered commercialization and distribution agreements with Nippon Shinyaku covering the U.S., Japan, and Europe, with potential milestones totalling US$1.50 billion. This combination of late-stage clinical success and a broad global partnership materially advances Capricor’s path from a purely clinical-stage company toward potential commercial execution. We’ll now examine...